Press Releases

Seattle, WA - Sep 6, 2005

Scienstist at Benaroya Research Institute Identifies Novel Cause of Allergy

Discovery of Trigger to Inflammation and Disease Progression in Asthma May Lead to New Therapeutic Approach; Published in Nature Immunology

In a report published online Sept. 4 in the journal Nature Immunology, a team lead by Benaroya Research Institute scientist Steven F. Ziegler, Ph.D., identified a new factor perpetrating the onset and progression of asthma. Along with Dr. Ziegler’s team at the Benaroya Research Institute, the work included investigators from the University of Washington and Stanford University School of Medicine1.

Ziegler’s group showed that a novel cytokine, Thymic Stromal Lymphopoietin (TSLP), is involved in initiating the inflammatory cascade that leads to the development of asthma and other allergic diseases. Current therapies for these diseases typically treat symptoms, not causes (i.e., through use of inhaled steroids). If TSLP proves to be the elusive initiating factor, these studies suggest that inhibiting TSLP may be an effective therapeutic intervention for asthma and other allergic inflammatory diseases.

The studies used model systems to show that TSLP was increased in lungs with asthma, that only those capable of responding to TSLP were affected by disease, and that expression of TSLP in the lung leads to the development of allergic asthma.

"We have identified a potentially very important trigger for allergic disease. The next step is to gain further understanding on how TSLP functions, and to determine whether it is a viable clinical target for asthma and other allergic diseases," said Dr. Ziegler. "The exciting news is that we may now be able to target a factor involved in the onset of disease."

About Virginia Mason Medical Center

Virginia Mason Medical Center, founded in 1920, is a non-profit comprehensive regional health care system that combines a primary and specialty care group practice of nearly 400 physicians with a 336-bed acute care Seattle hospital.

1 Baohua Zhou, Michael R Comeau, Thibaut De Smedt, H Denny Liggitt, Martin E Dahl, David B Lewis, Dora Gyarmait, Theingi Aye, Daniel J Cambpell, & Steven F Ziegler

Featured BRI Building Exterior 2024

About Benaroya Research Institute

Benaroya Research Institute (BRI) is a world leader in human immune system research. BRI works to advance the science that will predict, prevent, reverse and cure immune system diseases like allergies, asthma, cancer and autoimmune diseases. BRI accelerates discovery through laboratory breakthroughs in immunology that are then translated to clinical therapies. We believe that a breakthrough in one immune system disease can lead to progress against them all, and work tirelessly toward our vision of a healthy immune system for everyone. BRI is a world-renowned independent nonprofit research institute affiliated with Virginia Mason Franciscan Health and based in Seattle.

To learn more, visit benaroyaresearch.org and connect with us on Facebook, Instagram, Threads, LinkedIn, X and YouTube.